Variantyx specializes in data driven precision medicine. We are revolutionizing cancer and genetic disorder diagnoses, one patient at a time.
Genomic Unity® testing uses a single method for detection of multiple types of variants to provide one, unified clinical report. PCR-free whole genome sequencing is paired with in-silico analysis to identify small sequence changes, large structural variants, mitochondrial variants and tandem repeat expansions within a single sample. A complete analysis can be ordered directly, or a more targeted analysis can be selected followed by reflexing up to the complete analysis in case no initial results are identified.
Learn more at www.variantyx.com/diagnostic-testing/.
Genomic Unity® testing uses a single method for detection of multiple types of variants to provide one, unified clinical report. PCR-free whole genome sequencing is paired with in-silico analysis to identify small sequence changes, large structural variants, mitochondrial variants and tandem repeat expansions within a single sample. A complete analysis can be ordered directly, or a more targeted analysis can be selected followed by reflexing up to the complete analysis in case no initial results are identified.
Learn more at www.variantyx.com/diagnostic-testing/.
Location: Israel, Tel Aviv District, Herzliya
Employees: 51-200
Phone: +1 617-209-2090
Total raised: $123.5M
Founded date: 2014
Investors 1
| Date | Name | Website |
| - | Quark Vent... | quarkventu... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 29.04.2024 | - | $36M | - |
| 14.02.2022 | Series C | $41.5M | - |
| 22.11.2021 | Series C | $26M | - |
| 15.03.2021 | Series C | $20M | - |
Mentions in press and media 16
| Date | Title | Description |
| 29.04.2024 | Variantyx Raises $36M in Funding | Variantyx, a Framingham, MA-based company which specialises in molecular diagnostics, raised $36M in funding. Backers included Peregrine Ventures, Pitango HealthTech, New Era Capital Partners and Bosch Ventures. The round brought the total ... |
| 19.10.2023 | Variantyx Raises Additional Funding | Variantyx, a Framingham, MA-based company which specializes in genomic precision medicine, raised an additional funding of undisclosed amount. The round saw participation from Robert Bosch Venture Capital, Pitango HealthTech, New Era Capita... |
| 15.02.2022 | How we got here and how we get out: A Q&A with venture capitalist Melissa Bradley on the Black funding gap | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Last week I sat down with Melissa Bradley, managing partner at 1863 Ventures, to discuss the fund... |
| 14.02.2022 | Variantyx Secures $20M in Series C | BOSTON, MA, Variantyx is a CLIA/CAP laboratory providing Genomic Unity, a whole genome sequencing (WGS)-based testing program for diagnosis of rare inherited disorders. The series C funding round was led by GHS Fund. >> Click here ... |
| 14.02.2022 | Variantyx Secures $41.5M for Genetic Testing and Personalized Medicine | What You Should Know: – Variantyx, a technology-driven precision medicine company providing advanced genomic testing for the rare genetic disorders, reproductive health, and precision oncology markets, today announced they have secured $41.... |
| 14.02.2022 | Variantyx nabs $41.1M for tech-backed genomic analysis | Photo by MR.Cole_Photographer/Getty Images |
| 14.02.2022 | Precision medicine startup Variantyx lands $41.5M in funding to treat rare diseases using whole-genome sequencing | One in ten Americans suffers from a rare disease, according to the National Institutes of Health (NIH). The agency found that there are approximately 7,000 rare diseases affecting between 25 and 30 million Americans. That’s why Framingham, ... |
| 14.02.2022 | Variantyx Secures $41.5M in Series C-2 Funding | Variantyx, a Framingham, Mass.-based technology-driven precision medicine company providing advanced genomic testing for the rare genetic disorders, reproductive health, and precision oncology markets, secured $41.5M in series C-2 funding. ... |
| 22.11.2021 | Robert Bosch Venture Capital Invests Approx. $26M in Variantyx | Robert Bosch Venture Capital GmbH, the corporate venture capital company of the Bosch Group, completed an investment in Variantyx Inc., a Framingham, MA-based provider of advanced diagnostics and personalized treatment recommendations for o... |
| 25.03.2021 | Why Families Need the Closure Whole Genome Sequencing Provides | Haim Neerman, CEO of Variantyx. For medical practitioners expertly trained in the scientific methods of discovery, having a young patient with serious health complications from an undiagnosed condition is about as somber and frustrating as ... |
Show more